Voretigene neparvovec (Luxturna®)
Voretigene neparvovec (Luxturna®) is available for reimbursement under hospital pricing approval from August 2023. A Managed Access Protocol (MAP) is in place for voretigene neparvovec. This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of voretigene neparvovec under hospital pricing approval.
The prescribing of voretigene neparvovec (Luxturna®) for reimbursement under hospital pricing approval is confined to consultant ophthalmologists, with expertise in the care and treatment of patients with inherited retinal dystrophy, and the presence of or affiliation with a retinal surgeon experienced in sub-retinal surgery and capable of administering voretigene neparovoec (Luxturna®) in specialist centre(s), who have agreed to the terms of the MAP and have been approved by the HSE.
The approved prescriber must submit an application for individual reimbursement approval for each patient. Applications for individual reimbursement approval will only be considered from approved prescribers.
A copy of the HSE Managed Access Protocol for Voretigene neparvovec (Luxturna®) and application form for individual reimbursement approval can be found in the Related Files section below.
For further information, please contact email@example.com.